E

Enterome

76 employees

Enterome is a clinical-stage company developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases.

Basic info

Industry

biotechnology research

Sectors

Metagenomics
Biotechnology
Health Care
Inflammatory Bowel Diseases
Auto-immunity
Immunotherapies
Biopharma
Immuno-oncology
Life Science
Microbiome

Date founded

2011

Funding rounds raised

Total raised

$52M

from 26 investors over 26 rounds

E

Enterome raised $52M on June 25, 2020

Investors: Seventure Partners, Omnes and Principia SGR

E

Enterome raised undisclosed on January 4, 2018

Investors: Lundbeckfonden / Lundbeck Foundation, Bristol-Myers Squibb, UK, Principia SGR, Seventure Partners, European Investment Bank and Omnes

E

Enterome raised $33M on January 1, 2017

Investors: Lundbeckfonden / Lundbeck Foundation, Principia SGR, Seventure Partners, Bristol-Myers Squibb, UK and Omnes

E

Enterome raised $16M on April 20, 2016

Investors: Lundbeckfonden / Lundbeck Foundation, Seventure Partners and Omnes

E

Enterome raised $15M on May 1, 2014

Investors: Lundbeckfonden / Lundbeck Foundation, Omnes and Seventure Partners

E

Enterome raised $9.9M on March 23, 2012

Investors: Lundbeckfonden / Lundbeck Foundation, Seventure Partners, Omnes and Shire Pharmaceuticals

E

Enterome raised $2M on January 1, 2011

Investors: Inra - Institut national de la recherche agronomique (France) and Seventure Partners

FAQ